AddedRisk Factors
Medicare population due to the age restriction and annual phase in requirement. Accordingly, we would intend to seek a USPSTF grade for Galleri and, potentially, an NCD as additional preventative services. If we receive an NCD for Galleri or our other products and subsequently receive a USPSTF grade lower than A or B, it is possible that CMS would rescind the NCD.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedRisk Factors
In determining whether to provide coverage and reimbursement for Galleri, payors may consider the results of our clinical studies, including the NHS-Galleri Trial. The NHS-Galleri Trial did not meet its primary endpoint of statistically significant combined Stage 3 and 4 reduction. Even though the trial demonstrated a substantial reduction in stage 4 cancer diagnoses, increased stage 1 and 2 detection of deadly cancers, and four-fold higher cancer detection rate when compared to recommended screenings alone, payors may view the overall trial outcome unfavorably, which could adversely impact coverage decisions or reimbursement rates for Galleri. Any inability to secure favorable coverage and reimbursement decisions as a result of the NHS-Galleri Trial results, or otherwise, could materially harm our revenue and growth prospects.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedRisk Factors
•the perception among healthcare providers, payors, regulators, and the investment community regarding the clinical significance of clinical trial results, including instances where a trial does not meet its primary endpoint, even if clinically meaningful secondary endpoints are achieved, as occurred in our NHS-Galleri Trial; and
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedRisk Factors
•the willingness of healthcare providers and payors to prescribe or cover Galleri in light of the NHS-Galleri Trial not meeting its primary endpoint of statistically significant combined Stage 3 and 4 reduction, notwithstanding favorable secondary endpoint data.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RemovedRisk Factors
Further, we plan to improve our products to enhance performance, offerings, scalability, and/or cost of goods. However, we may not be successful in transitioning our products to a new or enhanced version or iteration. Product development involves a lengthy and complex process and we may be unable to commercialize, validate, or improve performance of any of our products on a timely basis, or at all. For example, to the extent an enhanced version of an existing product is developed, we may be required to conduct a non-inferiority study involving such enhanced version as compared to the relevant then-current version of the test using data (for example, clinical data and/or real world evidence data obtained through Galleri’s commercial use as an LDT), or could be required to undertake other regulatory requirements if the enhanced version is not considered similar enough to the then-
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
The results of our development efforts and clinical studies of our products conducted to date and ongoing or future studies of our current or future products may not be predictive of the results of later clinical studies, and interim results of a clinical study do not necessarily predict final results. Our interpretation of data and results from our clinical studies do not ensure that we will achieve similar or favorable results in future clinical studies. In addition, clinical data are often susceptible to various interpretations, analyses, and methodological limitations, and many companies that have believed their products performed satisfactorily in earlier clinical studies have nonetheless failed to replicate results in later clinical studies. Products in later future clinical studies may fail to show the desired safety and efficacy despite having success in previous clinical studies.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
For example, our PMA submission for Galleri requires clinical data, including certain data from our ongoing PATHFINDER 2 study, which we are conducting under an FDA-approved Investigational Device Exemption (“IDE”) application and our NHS-Galleri Trial. We may encounter difficulties enrolling or maintaining a sufficient number of participants in our current or future studies. Delays in our studies would cause us to delay completion
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
validating or generating revenue from our precision oncology offering, and we could experience reputational or other harms.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
planned clinical studies used to support our PMA submission, which could lead healthcare providers, payors, and others to lose confidence in the utility or benefit of Galleri and our other products and future products.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our success will depend on the market’s confidence that our products, including Galleri and, if successfully developed and launched, further enhanced versions of Galleri, and our precision oncology portfolio can provide reliable, high-quality results. We believe that participants, patients, customers, physicians, and regulators are
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
materially harmed. Although we carry insurance for damage to our properties and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
diagnostic development and commercialization. Our reliance on certain of these third parties reduces our control over our product development activities.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
we have employment agreements with certain key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract and incentivize highly qualified personnel on acceptable terms in a timely manner, or at all, our business and results of operations may suffer.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
In addition, in recent years, U.S. administrations have publicly supported potential trade proposals that may affect U.S. trade relations with other countries. It is unclear at this point how, if at all, such actions or other potential actions, including under the new U.S. Presidential administration, may impact our business or
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
We, along with companies with whom we engage in data sharing, including our service providers, are from time to time subject to cyberattacks and other cybersecurity incidents. While we do not believe that we have experienced any significant system failure, or cybersecurity incident to date, we may nonetheless be a target of such an attack, and if such an event were to occur and cause interruptions in our operations, or any of our third-party collaborators’ operations, it could result in a material disruption of our development programs, reputation, and business operations whether due to a loss, corruption, or unauthorized disclosure of our trade secrets, personal information, financial information, health information, or other proprietary or sensitive information, or other similar disruptions. For example, the loss of clinical study data from completed or ongoing clinical studies could result in delays in any regulatory clearance, approval, or certification efforts and significantly increase our costs to recover or reproduce the data, and subsequently commercialize our products. If we or our third-party collaborators, consultants, contractors, suppliers, or service providers were to suffer a cybersecurity incident or attack, for example, that resulted in the unauthorized access to or use or disclosure of personal or health
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedRisk Factors
Attacks on information technology systems are increasing in their frequency, levels of persistence, sophistication, and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. In particular, developments in artificial intelligence tools and computing power, are likely to increase the frequency and effectiveness of attacks. We may also experience cybersecurity incidents that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate cybersecurity incidents due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RewordedRisk Factors
It Further, it is possible that the early preliminary, interim or final data may not be as we expect, may be inconsistent with prior NHS-Galleri Trial data, or with other studies we have conducted, or may be unsuitable to the NHS, any of which could have a significant adverse impact on NHS or the success of our commercial efforts for Galleri, our ability to achieve FDA authorization at all or within our anticipated timelines, our ability to achieve CMS or private payor reimbursement or coverage, our brand and reputation, our business, and our growth prospects. FDA.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, Washington State has enacted a broadly applicable law to protect the privacy of personal health information known as the “My Health My Data Act,” which generally requires affirmative consent for the collection, use, or sharing of any broadly defines “consumer health data. data”, creates a private right of action to allow individuals to sue for violations of the law, imposes stringent consent requirements, and grants consumers certain rights with respect to their health data, including to request deletion of their information.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
The To this end, on May 6, 2024, the FDA proposed issued a final rule in an amendment to its regulations in October 2023 effort to clarify the FDA’s historical view that LDTs are medical devices subject to the requirements applicable to other IVDs, IVDs (the “LDT Final Rule”), and to phase out its enforcement discretion policy over a period of four years from issuance of the final rule, which would involve a phase-in of medical device requirements to these products over this time period. LDT Final Rule.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our PMA submission and a potential subsequent Potential rejection or material delay, delay of our PMA submission, including a requirement by the FDA to conduct additional studies or expand the enrollment of completed or ongoing studies, may reflect negatively on Galleri and the ongoing clinical studies used to support our PMA submission, which could lead healthcare providers, payors, and others to lose confidence in the utility or benefit of Galleri and our other products and future products.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our products or future products may not perform as expected, and the results of our clinical studies may not support the launch or use of our products or future products and may not comply with the requirements, or be replicated in later studies or in the post-market or real-world setting, required to support a commercial opportunity or for any necessary or desirable regulatory clearances, approvals, or certifications, or reimbursement or coverage. setting.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, as As a part of our overall public company preparedness efforts in connection with the Spin-Off in 2024, cybersecurity program, we underwent conduct a number of internal evaluations and independent, external third-party reviews of our cybersecurity program against audits and reviews, including under the NIST CSF 2.0 and NIST Privacy Framework, Frameworks, along with our ordinary course annual reviews under ISO 27001, SOC2 Type 2, PCI DSS, HIPAA, and other standards, in order to identify capabilities, gaps, and recommendations for improvement, and to compare our cybersecurity program to applicable requirements.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our short operating history as a company, evolving business strategies, rapid growth and significant events such as our separation from Illumina and the Restructuring Plan restructuring plan (“Restructuring Plan”) approved by our Board of Directors (the “Board”) designed to reprioritize our resources to focus on our core MCED business and reduce overall spend as we pursue a PMA approval from the FDA for Galleri and broad reimbursement, may make it difficult to evaluate our current business or our future success and the risks and challenges we may encounter, and may increase the risk that we will not continue to grow at or near historical rates.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
It is possible that the early preliminary, interim Any unexpected, unsuitable, or final data may not be as we expect, may be inconsistent with prior NHS-Galleri data, or with other studies we have conducted, or may be unsuitable to the NHS, any of which results could have a significant adverse impact on the success of our commercial efforts for Galleri, our ability to achieve FDA authorization at all or within our anticipated timelines, our ability to achieve CMS or private payor reimbursement or coverage, our brand and reputation, our business, and our growth prospects.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, the potential commercialization of Galleri with the NHS, subject to the full results of the NHS-Galleri Trial, Trial which we expect to report in mid-2026, will be considered by the government of the United Kingdom and may be delayed or otherwise impacted if there is a change in depending on the circumstances and the composition of the government in at the United Kingdom. time of consideration.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Noncompliance In addition to potential fines, noncompliance with applicable foreign privacy laws, such as the GDPR, would also adversely affect may result in regulatory investigations, orders to cease/ change our data processing activities, enforcement notices, assessment notices (for a compulsory audit), civil claims (including class actions) and/or damage to the public perception of GRAIL’s data stewardship practices and policies, which could impair our business and prospects with other foreign health systems and governments.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Specifically, this final rule, The QMSR, which replaced the FDA expects to go into effect on February 2, 2026, replaces the QSR with the FDA’s former Quality Management System Regulation (“QMSR”), (“QSR”), sets forth the FDA’s cGMP requirements for medical devices, and among other things, incorporates by reference certain elements of the quality management system requirements of ISO 13485:2016.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although the FDA has stated that the standards contained in ISO 13485:2016 are substantially similar to those set forth in the QSR, Accordingly, it is remains unclear the extent to which this final rule, once effective, could the QMSR may impose additional or different regulatory requirements on us that could increase the costs of compliance or otherwise create market pressure that may negatively affect our business.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
As a result, any disruption at our North Carolina facility could materially adversely affect our ability to process tests and return results to patients, and our revenue, operations, business and prospects could be materially harmed.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
It is possible that the FDA, among other things, may could disagree with our interpretation of data we have relied on to support our LDT launches for our intended uses.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
To achieve compliance with SOX Section 404 within the prescribed period, we will be are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedMD&A
across this clinical program and from our commercial experience, including through partnerships with leading healthcare systems, employers, digital health platforms, payors, and life insurance providers.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedMD&A
Recently we announced results from two of our large clinical trials, PATHFINDER 2 and NHS-Galleri Trial, and included certain results from those studies in our pre-market approval application (“PMA”) to the Food and Drug Administration (“FDA”), the last module of which we submitted in January 2026. Performance and safety data focused on the first approximately 25,000 participants of our approximately 35,000 participant PATHFINDER 2 study were presented at the European Society for Medical Oncology (“ESMO”) in October 2025 (the “PATHFINDER 2 Initial Results”) and demonstrated that adding Galleri to recommended (breast, cervical, colorectal and lung) screenings led to a cancer detection rate more than seven-fold increase in the number of cancers found within a year, and an approximately three-fold increase when prostate screening was included. Results from the full approximately 35,000 participants in the PATHFINDER 2 study were generally consistent with the results presented at ESMO. We also announced topline results from our three year, randomized control NHS-Galleri Trial which demonstrated a substantial reduction in stage 4 cancer diagnoses, increased stage 1 and 2 detection of deadly cancers, and four-fold higher cancer detection rate when compared to recommended screenings alone, although the primary endpoint of statistically significant combined stage 3 and 4 reduction was not observed. However, there was a favorable trend toward fewer combined stage 3 and 4 cancers in a pre-specified group of 12 deadly cancers in the intervention arm after the prevalent screening round. The PATHFINDER 2 Initial Results and the performance and safety metrics from the first year (prevalent screening round) of our NHS-Galleri Trial (“NHS-Galleri Prevalent Screening Round Results”) were included in our PMA submission, along with results of a bridging study.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedMD&A
We designed Galleri to detect cancer early, when it is more amenable to curative treatment, and we launched Galleri in the United States in mid-2021. Galleri works by detecting DNA fragments shed into the bloodstream by tumor cells and analyzing specific methylation patterns that can be used to both identify a general cancer signal and localize that signal to a specific organ or tissue type. We have sold approximately 475,000 commercial Galleri tests through December 31, 2025, including more than 185,000 in 2025, which have detected some of the most aggressive cancers in early stages including, among others, endometrial, esophageal, gastrointestinal, head and neck, liver, pancreatic, and rectal cancers.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedMD&A
As an early pioneer of MCED testing, we have established strong relationships within the cancer and primary care community, including through partnerships with academic and community medical centers, key opinion leaders, and governmental policy and advocacy partners. We have shared evidence supporting our MCED testing at renowned medical conferences, such as the American Association of Cancer Research (“AACR”), American Society of Clinical Oncology (“ASCO”), ESMO, and American Academy of Family Physicians (“AAFP”). We have also published results from our studies in leading scientific and medical journals, including The Lancet, Nature, Nature Medicine, Cancer Cell, and The Lancet Oncology.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedMD&A
On October 18, 2025, we entered into a securities purchase agreement (the "Purchase Agreement") with certain investors for the private placement of (i) 2,640,970 shares of GRAIL's common stock at a price of $70.05 per share and (ii) pre-funded warrants to purchase an aggregate of 1,998,573 shares of GRAIL’s common stock (the "Pre-Funded Warrants") at a purchase price of $70.049 per Pre-Funded Warrant, which represents the per share price for the common stock less the $0.001 exercise price. The PIPE closed on October 21, 2025, at which time we received aggregate net proceeds of $311.3 million, after deducting issuance costs of $13.7 million.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedMD&A
In addition, in connection with the Purchase Agreement, we entered into a Registration Rights Agreement with all of the investors (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, we filed a registration statement on Form S-3 with the SEC on November 13, 2025 for purposes of registering the resale of the shares and the shares of common stock issuable upon exercise of the Pre-Funded Warrants purchased in the private placement.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedMD&A
On November 14, 2025, we entered into an equity distribution agreement (“Equity Distribution Agreement”), with certain sales agents, establishing an At the Market Equity Distribution Program, under which we may offer and sell shares of our common stock, having an aggregate offering price of $300.0 million or up to 6,900,000 of common stock shares (the “ATM Program”).
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedMD&A
During the year ended December 31, 2025, we issued 1,169,218 shares of our common stock pursuant to the ATM Program and we received aggregate net proceeds of $107.5 million, after deducting issuance costs of $3.2 million. As of December 31, 2025, $189.3 million worth of shares of common stock remained available for sale pursuant to the ATM Program.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedMD&A
In October 2025, we announced a strategic collaboration with Samsung C&T Corporation (“Samsung C&T”), Samsung Electronics Singapore Pte. Ltd. (together with Samsung C&T, the “Samsung Investors”) and Samsung Electronics Co., Ltd. (“Samsung Electronics”). As part of this strategic collaboration, we and Samsung C&T intend to work as exclusive partners to commercialize Galleri in Korea and, potentially, other key Asian markets, including Japan and Singapore. In addition, we and Samsung Electronics intend to explore potential additional strategic and operational collaborations, such as supporting longitudinal genomic-lifestyle clinical research and the integration of Samsung Electronics’ health data platform with our technologies and data.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedMD&A
In connection with this strategic collaboration, we entered into a stock purchase agreement (the “Samsung Stock Purchase Agreement”), with the Samsung Investors and Samsung Electronics, providing for the issuance and sale by us to the Samsung Investors in a private placement of 1,570,308 shares of our common stock, at a purchase price of $70.05 per share, upon the terms and conditions set forth in the Samsung Stock Purchase Agreement, for aggregate gross proceeds of approximately $110.0 million (the “Samsung Investment”). The Samsung Investment is subject to the satisfaction of certain closing conditions set forth in the Samsung Stock Purchase Agreement, including, but not limited to the satisfaction of certain regulatory approvals or clearances, including with respect to the Committee on Foreign Investment in the United States.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedMD&A
We intend to use the net proceeds from all our equity offerings to fund our commercial activities and reimbursement efforts, as well as for working capital and other general corporate purposes.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
AddedMD&A
We entered into or adopted agreements that provide a framework for the relationship between us and Illumina in connection with the Spin-Off. Refer to Note 1 — Organization And Description Of Business in Item 8 in this Annual Report on Form 10K.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RemovedMD&A
A detailed discussion comparing our results of operations for the years ended December 31, 2023 and January 2, 2022 can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our final Information Statement filed with our Registration Statement on Form 10, as amended, as filed with the SEC.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedMD&A
On June 24, 2024, Illumina completed the Spin-Off, as described above. See Note 1 — Organization And Description Of Business for details. In connection with the Spin-Off, certain equity and liability classified awards were converted in accordance with the employee matters agreement, as further described in Note 7 — Stock-Based Compensation. As a result of the separation, our member’s equity balance was reclassified to additional paid-in capital.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedMD&A
While GRAIL was a subsidiary of Illumina, GRAIL’s fiscal year was the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. References to “fiscal year 2023” refer to the period from January 2, 2023 to December 31, 2023, and “fiscal year 2024” refer to the period from January 1, 2024 to December 31, 2024. Upon the closing of the Spin-Off, GRAIL adopted a fiscal year end of December 31.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedMD&A
opportunities and we have begun expansion in select additional geographies through distributors. We expect to continue selectively engaging with international opportunities over time.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedMD&A
•Leverage our operational infrastructure. We have made significant investments to build a scalable infrastructure capable of meeting significant demand while satisfying applicable certification requirements. Our Durham, North Carolina facility is able to process a substantial number of tests
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedMD&A
On July 13, 2022, the European General Court ruled that the European Commission had jurisdiction under the European Union Merger Regulation to review the Acquisition. Additionally, on September 6, 2022, the European Commission issued a decision prohibiting the Acquisition. These decisions constituted substantive changes in circumstances that would more likely than not reduce the fair value of goodwill. We recognized a goodwill impairment for $4.7 billion in 2022. In the third quarter of 2023, we concluded the sustained decrease in Illumina’s stock price and overall market capitalization during the quarter was a triggering event indicating the fair value of GRAIL might be less than its carrying amount that led us to test goodwill for impairment. We recognized an additional goodwill impairment of $608.5 million in 2023 primarily due to changes to expected timing of revenue and a higher discount rate. In the second quarter of 2024, prior to the Spin-Off, the approval of the Spin-Off by Illumina’s board of directors represented a potential indicator of impairment which also aligned with the timing of Illumina’s annual goodwill impairment test date for 2024. We recognized a goodwill impairment of $888.9 million as a result of the impairment assessment, primarily due to changes to the forecast of GRAIL’s value and the method for valuing GRAIL.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedMD&A
In conjunction with the third quarter of 2023 goodwill impairment assessment described above, the Company also evaluated the IPR&D intangible asset for potential impairment. Based on the impairment test performed, the Company recognized an impairment of $110.0 million, primarily due to a decrease in projected cash flows and a higher discount rate selected for the fair value calculation. In conjunction with Illumina’s second quarter of 2024 goodwill impairment assessment, the IPR&D intangible asset of the GRAIL reporting unit was evaluated for potential impairment by Illumina prior to the Spin-Off. Based on the impairment test performed, the Company recognized an impairment of $420.0 million primarily due to changes to revenue projections and the discount rate utilized. Subsequent to the Spin-Off, the Company performed a portfolio review and determined to decrease investment in the development of the IPR&D asset, which impacted the amount and timing of expected future cash flows attributable to IPR&D which represented a potential impairment indicator. Based on the impairment test performed, the Company recognized an additional impairment of $112.0 million, primarily due to a decrease in projected cash flows.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedMD&A
Upon closing of the Acquisition, as a wholly owned subsidiary of Illumina, we were no longer subject to U.S. income tax on a standalone basis and U.S. income tax was combined into Illumina’s consolidated income tax return as a subsidiary of Illumina. However, for financial statement purposes, we have elected to compute our income tax provision, including current and deferred taxes, as if we filed a separate income tax return and were not included in Illumina’s consolidated return for the period GRAIL was owned by Illumina. Including the provision for income taxes in our standalone financials is more representative of our financial position as a standalone company. As such, the income tax provisions and related deferred tax assets and liabilities reflected in our financial statements for the periods ending December 31, 2023 and January 1, 2023 have been estimated as if we were a separate taxpayer.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedMD&A
Under this method, various tax attributes, such as net operating losses and tax credits, are also presented on a separate return basis. For income tax purposes, since we were not a separate taxpayer and merely a subsidiary of Illumina, these tax attributes, including net operating losses and tax credits, are the property of
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedMD&A
Illumina and have either already been utilized by Illumina in its consolidated or combined income tax returns or will be utilized by Illumina in its returns in the future. Accordingly, such tax attributes will not be available to us as a standalone entity on our income tax returns in the future; therefore, in connection with the Spin-off, we recorded an entry to additional paid in capital in order to remove the tax-effected deferred tax assets, net of any valuation allowance, for the tax attributes that remained the property of Illumina. Following the Spin-off, as a standalone entity, GRAIL files tax returns on its own behalf and its deferred taxes and actual income tax rate may differ from those in historical periods.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedMD&A
The following table summarizes our results of operations for fiscal year 2024 and fiscal year 2023.
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RemovedMD&A
Research and development expenses for fiscal years 2024 and 2023 were as follows:
Read it in 10-K Mar 5, 2025 at sec.govopen_in_new
RewordedMD&A
The decrease in sales and marketing expenses of $8.3 $37.3 million or 24% was primarily attributable to a decrease of $2.5 million in compensation expenses of $26.1 million, primarily related due to a $17.4 million decrease in salaries and wages of $4.9 million, wages, a $4.8 million decrease in severance and benefits, and a $4.4 million decrease in stock-based compensation of $2.2 million, and a decrease of $0.3 million in variable compensation expense expense, primarily due to the reduction in workforce reductions related to the Restructuring Plan, partially offset by a $4.9 million increase Plan implemented in severance and benefits related to the Restructuring Plan. 2024.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedMD&A
We calculate Adjusted EBITDA as net income (loss) loss adjusted to exclude interest (income) expense, income tax expense (benefit), depreciation, impairment of goodwill and intangible assets, and amortization of intangible assets, which represent stock-based compensation, depreciation, goodwill and intangible assets resulting impairment, restructuring, interest income, benefit from pushdown accounting, income tax expense, and legal and professional services fees costs related to the Acquisition and corresponding antitrust litigation, including compliance with the hold separate arrangements imposed by the European Commission Commission, and our divestment from Illumina, restructuring charges, and stock-based compensation. Illumina.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedMD&A
In these studies, Galleri demonstrated an ability to detect a shared cancer signal across more than 50 Our multi-cancer early detection test (“Galleri”) can screen for many types of cancer, accurately predict predicting the specific organ or tissue type where the cancer signal originated, and yield originated (the “Cancer Signal of Origin”, or “CSO”), with high positive predictive values (“PPV”) and low false positive rates, all from a simple blood draw.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedMD&A
We expect our sales and marketing expenses to decrease increase following the release of positive study results as we invest in the near term following implementation initiatives to drive awareness and demand generation of the Restructuring Plan in the third Galleri and fourth quarter 2024, and then to remain flat-to-increasing and continue to decrease as a percentage of revenue over the next three years and long term.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedMD&A
The A decrease in clinical studies laboratory supplies and research collaborations of $10.7 $28.5 million was primarily due to driven by the substantial completion of the development and validation of our automated platform, the completion of enrollment in our the PATHFINDER 2 study and the completion of final study visits in our the NHS-Galleri Trial. Trial in 2024.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of screening revenue (exclusive of amortization of intangible assets) as a percent of revenue decreased in 2024 primarily 2025 mainly due to improved efficiency the reduction in variable costs of Galleri testing related to scalability with increased Galleri sales volume. performed on our automated platform, partially offset by a 6% decrease in ASP and higher sample reprocessing costs.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedMD&A
We expect our G&A expenses to decrease increase as we continue to invest in corporate infrastructure to support public company operations and the near term following implementation commercialization of the Restructuring Plan in the third Galleri and fourth quarter 2024, and then remain flat-to-increasing and to continue to decrease as a percentage of revenue over the next three years and long term.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedMD&A
The In the United Kingdom, NHS England (which is being merged with the Department of Health and Social Care) (the “NHS”) will evaluate the final results from the NHS-Galleri Trial, which are expected to be available in 2026, Trial before determining whether to implement the Galleri test in the NHS.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedMD&A
The increase decrease in general and administrative expenses of $13.6 $54.8 million or 26% was primarily attributable to an increase of $12.3 million decreases in legal and professional services expenses primarily associated with divestiture and compensation related advisory costs related to our Spin-Off completed on June 24, 2024. expenses.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedMD&A
On June 24, 2024, Illumina The Spin-Off was completed the previously announced spin-off of GRAIL (the “Spin-Off”) through a distribution of approximately 85.5% of our outstanding common stock to the holders of record of Illumina’s common stock as of the close of business on June 13, 2024 (the “Distribution”). “Distribution”), which resulted in the issuance of 31,049,148 shares of common stock.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedMD&A
The increase of $3.0 million A decrease in allocated expenses was of $11.2 million primarily attributable related to higher ongoing cost reduction efforts, which resulted in lower software, IT, and facilities expenses being allocated to the research and development function. function, as well as reduced headcount.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in cost of screening revenue (exclusive of amortization of intangible assets) of $15.3 $10.0 million or 16% was primarily driven by an a 36% increase in test volume. Galleri sales volume, partially offset by a reduction in variable costs of Galleri testing performed on our automated platform.
Read it in 10-K Mar 12, 2026 at sec.govopen_in_new